Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Ann MacLaren"'
Publikováno v:
BMC Nursing, Vol 20, Iss 1, Pp 1-12 (2021)
Abstract Aims To understand the experiences of nursing students and academic staff of an intervention to decrease burnout and increase retention of early career nurses, in order to identify acceptability and feasibility in a single centre. Background
Externí odkaz:
https://doaj.org/article/a1c4f15d97cd403b9d9b94975fd13eb7
Autor:
Paul G. Richardson, Amit Khot, Jeffrey A. Zonder, Steven D. Reich, Ann MacLaren, Jacob P. Laubach, Ashraf Z. Badros, Dharminder Chauhan, Todd M. Zimmerman, Simon J. Harrison, Nancy Levin, Krystal Bergin, Andrew Spencer, Mohit Trikha
Publikováno v:
British Journal of Haematology. 180:41-51
Marizomib (MRZ) is an irreversible, pan-subunit proteasome inhibitor (PI) in clinical development for relapsed/refractory multiple myeloma (RRMM) and glioma. This study analysed MRZ, pomalidomide (POM) and low-dose dexamethasone (Lo-DEX) [PMD] in RRM
Publikováno v:
Nurse Education in Practice
Co-production is a process employed to solve complex issues, recognising the expertise of all stakeholders. This paper reports on co-production undertaken by nursing students, early career nurses and researchers as part of a larger study to design an
Autor:
Zeba Singh, Paul G. Richardson, Mohit Trikha, Ann MacLaren, Young Kwok, Ashraf Z. Badros, Parameswaran Hari, Binod Dhakal
Publikováno v:
British journal of haematology. 177(2)
Summary Marizomib, a natural marine product, is an irreversible proteasome inhibitor currently under investigation in relapsed-refractory multiple myeloma (RRMM) and malignant glioma. Central nervous system-multiple myeloma (CNS-MM) is a rare manifes
Autor:
Kaijun Di, Vivek Abraham, Ann MacLaren, Daniela A. Bota, Francis Burrows, Mohit Trikha, Annick Desjardins, G. Kenneth Lloyd
Publikováno v:
Di, K; Lloyd, GK; Abraham, V; MacLaren, A; Burrows, FJ; Desjardins, A; et al.(2016). Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier. NEURO-ONCOLOGY, 18(6), 840-848. doi: 10.1093/neuonc/nov299. UC Irvine: Retrieved from: http://www.escholarship.org/uc/item/3td7095n
Neuro-oncology, vol 18, iss 6
Neuro-oncology, vol 18, iss 6
Author(s): Di, Kaijun; Lloyd, G Kenneth; Abraham, Vivek; MacLaren, Ann; Burrows, Francis J; Desjardins, Annick; Trikha, Mohit; Bota, Daniela A | Abstract: BackgroundThe proteasome plays a vital role in the physiology of glioblastoma (GBM), and protea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::189cad27274943aad25e5e0de0d7bc38
http://www.escholarship.org/uc/item/3td7095n
http://www.escholarship.org/uc/item/3td7095n
Publikováno v:
Cancer Research. 78:835-835
CD22 is a cell surface protein with expression restricted to mature B lineage cells. It is highly expressed on a wide range of B cell malignancies including NHL (non-Hodgkin's lymphoma), DLBCL (diffuse large B cell lymphoma), follicular lymphoma and
Autor:
Julie-Ann MacLaren
Publikováno v:
Nurse education in practice. 28
Supervised practice as a mentor is currently an integral component of nurse mentor education. However, workplace education literature tends to focus on dyadic mentor-student relationships rather than developmental relationships between colleagues. Th
Autor:
Julie-Ann MacLaren
Publikováno v:
International Journal of Palliative Nursing. 9:538-543
Lymphoedema treatment has long been associated with large lymphology clinics in Austria and Germany, where many therapists and patients have made pilgrimages to experience or learn techniques for managing the condition. Although these clinics have un
Autor:
Todd M. Zimmerman, Simon J. Harrison, Andrew Spencer, Ashraf Badros, Krystal Bergin, Ann Maclaren, Steven D. Reich, Amit Khot, Jacob P. Laubach, Kenneth C. Anderson, Jeffrey A. Zonder, Paul G. Richardson, Mohit Trikha
Publikováno v:
Blood. 128:3326-3326
Marizomib (MRZ) is a novel, irreversible, pan subunit proteasome inhibitor (PI) with preclinical evidence demonstrating in vitro and in vivo activity in multiple myeloma (MM). This study was designed to evaluate the safety and antimyeloma activity of
Autor:
Ashraf Badros, Young Kwok, Hari Parameswaran, Mohit Trikha, Zeba N. Singh, Paul G. Richardson, Binod Dhakal, Ann Maclaren
Publikováno v:
Blood. 128:2118-2118
Marizomib, a natural marine product, is an irreversible proteasome inhibitor (PI) that has distinct advantages over the currently approved PIs in that it irreversibly inhibits all three enzymatic activities of the proteasome and has been demonstrated